跳至主要内容
临床试验/NCT00725387
NCT00725387已完成不适用

Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy

Stanford University5 个研究点 分布在 5 个国家目标入组 214 人开始时间: 2007年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
214
试验地点
5
主要终点
Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.

研究概览

简要总结

Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer detection was not attempted to date. We hope to learn what is the best approach for detection of cancer and thus to improve cancer treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than 18-year-old, diagnosed with cancer
  • Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them

排除标准

  • Patients who cannot complete a PET/CT scan
  • Pregnant women
  • Healthy volunteers
  • Patients participating in other research studies
  • The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.

结局指标

主要结局

Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.

时间窗: not defined

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验